Considerable differences in management of cytomegalovirus infection in patients with biliary atresia

Abstract

AbstractObjectivesPatients with biliary atresia (BA) and ongoing cytomegalovirus (CMV) infection may have poorer outcomes after Kasai portoenterostomy than uninfected patients. Still, there is no consensus on the usefulness of viral testing and antiviral treatment (AVT). This study aims to explore the need for future research on AVT for CMV infection by assessing how CMV infection in BA patients is managed in different centers.MethodsAn online questionnaire with 10 questions was offered to participants at an international congress on BA, organized in collaboration with the European Reference Network for rare liver diseases in 2022. Answers to questions were either dichotomic or multiple choices of different numeric intervals. Ongoing CMV infection was defined by detecting cytomegalovirus‐immunoglobulin M (CMV‐IgM) in serum or cytomegalovirus‐deoxyribonucleic acid (CMV‐DNA) by polymerase chain reaction in blood or urine.ResultsThere were 43 respondents from 36 centers in 26 countries. The total number of BA patients per year was between 208 and 380 from centers with 0–5 to >20 BA patients yearly (median 6–10). CMV infection was tested in 27 centers (75%), of which 18 (67%) use AVT. The rate of CMV infection varied between 0%–5% and 40%–50% (median 5%–10%). Willingness to treat the infection did not differ between centers with low and high rates of CMV infection.ConclusionsMost centers test for CMV infection, and a considerable proportion use AVT despite the lack of evidence of its benefits. A future randomized study on treating CMV infection in BA patients is necessary and feasible.